03 October 2018
Vol 10, Issue 461
  • Perspective

    • Regulating 3D-printed medical products

      There are a number of key considerations in the U.S. regulatory landscape regarding approval of 3D-printed medical devices and biologics.

  • Research Articles

    • Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals

      Anti-α4β7 integrin therapy results in attrition of lymphoid aggregates within the gastrointestinal tract of HIV-1–infected individuals with IBD.

    • An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo

      A nanoreporter noninvasively detects endolysosomal lipids, revealing that short-term changes in diet have enduring effects on hepatic macrophages.

    • p95HER2–T cell bispecific antibody for breast cancer treatment

      T cell bispecific antibodies against an isoform of HER2 effectively target many HER2-expressing tumors but not normal tissues.

    • Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease

      Mutant huntingtin suppression with antisense oligonucleotides reverses cognitive impairments in a mouse model of Huntington’s disease.

    • GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models

      There are no alterations in GABAA receptor availability in adults with autism spectrum disorder or in commonly used rodent models of the condition.

  • Editors' Choice

    • Astrocyte dysfunction and compulsive behavior

      Molecular, cellular, and circuit physiology studies identify a potential new therapeutic target for compulsive behavior disorders, involving dysfunctional neuron-astrocyte interactions within striatal microcircuits.

About The Cover

Cover image expansion

ONLINE COVER Aggravating Aggregates. Eradicating HIV in infected patients will likely require disrupting the reservoir of infected T cells in the gastrointestinal tract. One approach may be targeting cells expressing the integrin α4β7. Uzzan et al. studied patients with inflammatory bowel disease (IBD) that were also infected with HIV. They found that anti-α4β7 therapy (an approved therapy for IBD) disrupted lymphoid aggregates in the gut, such as the one pictured here. The anti-integrin therapy was well-tolerated and could possibly be used to root out HIV in the gut. [CREDIT: UZZAN ET AL./MOUNT SINAI SCHOOL OF MEDICINE]